HR positive + HER-2 negative

P2/3, N=316, Completed, Solti Group | Active, not recruiting --> Completed

MONARCH-2 trial data are not generalisable to this real-world cohort, which had notably shorter OS, TFS and CFS that could not be explained by differences in measured patient characteristics.

At present, there is no standardized treatment strategy for overcoming CDK4/6i resistance. This article systematically reviews current post-CDK4/6i therapeutic strategies, including next-generation endocrine therapies (e.g., oral SERDs), targeted agents directed at the PI3K/AKT/mTOR axis, AKT inhibitors, and antibody-drug conjugates (ADCs), and discusses potential future therapeutic directions.

Patients who receive CDK4/6 inhibitors for breast cancer experience a low but measurable risk of new-onset atrial arrhythmias. There was no significant difference in new-onset AA risk between agents. Prospective studies are needed to define mechanisms and guide monitoring strategies.

Notably, compound 1l showed poor cell-free potency (IC₅₀ = 202 nM) but significant whole-cell activity (IC₅₀ = 37.79 nM), highlighting improved lipid bilayer penetration. These findings validate the potential of piperazine-linked sulfamate derivatives as potent STS inhibitors that can offer new paths for hormone-dependent breast cancer therapy.

ER-Predict represents a robust assay with potential utility in early stage HR-positive/HER2-negative breast cancer. Its consistent ability to identify high-risk patients supports further investigation as a decision-support tool to guide treatment intensification in clinically low-risk HR-positive/HER2-negative disease.

In HR-positive HER2-negative metastatic breast cancer, no statistically significant negative association was observed in terms of survival and prognosis when switching from ribociclib to palbociclib after toxicity. Switching may be considered in selected patients during the treatment.

Compared with patients without recurrence, those with early recurrence showed a significantly higher prevalence of high-risk MP results and Luminal B BP subtype. High-risk MP/Luminal B BP subtype suggested an association with early recurrence in patients with HR + /HER2- early breast cancer.

Although pCR was not associated with a lower overall risk of CNS recurrence, it predicted a reduced risk in HER2-positive disease. Isolated CNS relapse predominated, suggesting a sanctuary effect.

Although pCR is not a validated surrogate for long-term survival in this specific subtype, our findings suggest that statins may biologically enhance short-term chemosensitivity, potentially through mevalonate pathway inhibition and modulation of the tumor microenvironment. These preliminary results support the need for larger prospective studies to further elucidate the role of statins as adjunctive agents in breast cancer management.

Patients with TN EZH2low tumours benefit more from ddAC, while EZH2high have a better outcome after TAC. High tubulin expression may predict docetaxel benefit if adjusted for sTILs. Further research with more patients is needed to find the best use of these biomarkers.

P4, N=206, Completed, Beni-Suef University